Medicare will start covering obesity drugs for the first time. Here's what patients should know

The development is expected to unlock millions of additional patients for Novo Nordisk and Eli Lilly by expanding access to medications that were previously unaffordable or out of reach for seniors, potentially supporting future demand. While no financial figures are provided, the outlook implication is modestly positive for the two companies.

Analysis

The development is expected to unlock millions of additional patients for Novo Nordisk and Eli Lilly by expanding access to medications that were previously unaffordable or out of reach for seniors, potentially supporting future demand. While no financial figures are provided, the outlook implication is modestly positive for the two companies.